Prebiotic Inulin for Late-Reproductive Individuals
for Obesity & Overweight
1 location in Washington D.C.
Sponsor: George Washington University
Sex: Female·Age: 40 - 55
Code: NCT07724522·Recruiting·Listed Jul 24, 2026
Paid Clinical Trials in District of Columbia
District of Columbia has 838 paid clinical trials enrolling now across cities including Washington D.C., Georgetown and Multiple Locations. Search by condition, age, or phase to find compensated research studies accepting participants near you.
Research sites in District of Columbia include Children's National Research Institute, Georgetown University and National Cancer Institute (NCI), running studies across oncology, cardiology, neurology, and more. The most actively recruiting conditions are Breast Cancer, Sickle Cell Disease, Stroke, High Grade Glioma — browse the full list or use the filters to match your diagnosis. Both patients and healthy volunteers may qualify. Most studies offer compensation for time and travel.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Filter results
Newly added in District of Columbia
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials
for Duchenne Muscular Dystrophy (DMD)
Sites in Washington D.C. +8 more locations
Sponsor: Vanderbilt University Medical Center
Sex: All·Age: All ages
Code: NCT07674758·Recruiting·Listed Jun 30, 2026
Randomized Evaluation of Voucher Interventions for Value and Effectiveness (REVIVE) in Philippines
for Food Insecurity
1 location in Washington D.C.
Sponsor: International Food Policy Research Institute
Sex: All·Age: 0 Months - 99
Code: NCT07640594·Recruiting·Listed Jun 10, 2026
Home-based Vision Rehabilitation Guided by Brain Imaging
for Visual Field Defect
1 location in Washington D.C.
Sponsor: Georgetown University
Sex: All·Age: 18+
Code: NCT07635329·Recruiting·Listed Jun 9, 2026
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
for Myelofibrosis
Drug: Ruxolitinib
Sites in Washington D.C. +29 more locations
Sponsor: Takeda
Sex: All·Age: 18+
Code: NCT07623161·Phase 3·Recruiting·Listed Jun 3, 2026
756 clinical trials
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
for Obesity
Drug: NNC0487-0111
Sites in Washington D.C. +205 more locations
Sponsor: Novo Nordisk A/S
Sex: All·Age: 18+
Code: NCT07567001·Phase 3·Recruiting·Listed May 2026
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
for Urothelial Cancer
Drug: PF-08634404
Sites in Washington D.C. +94 more locations
Sponsor: Pfizer
Sex: All·Age: 18+
Code: NCT07421700·Phase 1, Phase 2·Recruiting·Listed Feb 2026
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
for Solid Tumors
Drug: INCB161734
Sites in Washington D.C. +67 more locations
Sponsor: Incyte Corporation
Sex: All·Age: 18+
Code: NCT07522073·Phase 3·Recruiting·Listed Apr 2026
Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)
for Hepatitis
Drug: Larsucosterol
Sites in Washington D.C. +83 more locations
Sponsor: Bausch Health Americas, Inc.
Sex: All·Age: 18+
Code: NCT07428538·Phase 3·Recruiting·Listed Feb 2026
A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
for Moderate to Severe Glabellar Lines
Drug: IPN10200
Sites in Washington D.C. +40 more locations
Sponsor: Ipsen
Sex: All·Age: 18 - 80
Code: NCT07435428·Phase 3·Recruiting·Listed Feb 2026
A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
for Adenovirus Infections
Sites in Washington D.C. +31 more locations
Sponsor: SymBio Pharmaceuticals
Sex: All·Age: 2 Months+
Code: NCT07387367·Phase 3·Recruiting·Listed Feb 2026
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
for Obesity or Overweight
Drug: Enicepatide
Sites in Washington D.C. +34 more locations
Sponsor: Hoffmann-La Roche
Sex: All·Age: 18+
Code: NCT07351058·Phase 3·Recruiting·Listed Jan 2026
Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study
for Ventricular Arrythmia
Sites in Washington D.C. +26 more locations
Sponsor: AtaCor Medical, Inc.
Sex: All·Age: 18+
Code: NCT07324031·Recruiting·Listed Jan 2026
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
for CRC (Colorectal Cancer)
Drug: Bevacizumab
Sites in Washington D.C. +69 more locations
Sponsor: Incyte Corporation
Sex: All·Age: 18+
Code: NCT07284849·Phase 3·Recruiting·Listed Dec 2025
A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older
for Clostridioides Difficile Associated Disease
Sites in Washington D.C. +134 more locations
Sponsor: Pfizer
Sex: All·Age: 65+·Accepts healthy volunteers
Code: NCT07282665·Phase 3·Recruiting·Listed Dec 2025
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
for Diabetic Peripheral Neuropathic Pain
Sites in Washington D.C. +69 more locations
Sponsor: Vertex Pharmaceuticals Incorporated
Sex: All·Age: 18 - 80
Code: NCT07231419·Phase 3·Recruiting·Listed Nov 2025
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
for Focal Segmental Glomerulosclerosis
Sites in Washington D.C. +65 more locations
Sponsor: Boehringer Ingelheim
Sex: All·Age: 12+
Code: NCT07220083·Phase 3·Recruiting·Listed Oct 2025
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
for Carcinoma, Transitional Cell
Sites in Washington D.C. +61 more locations
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT07218380·Phase 3·Recruiting·Listed Oct 2025
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
for Breast Neoplasms
Sites in Washington D.C. +117 more locations
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT07174336·Phase 3·Recruiting·Listed Sep 2025
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
for Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Drug: Coramitug
Sites in Washington D.C. +59 more locations
Sponsor: Novo Nordisk A/S
Sex: All·Age: 18+
Code: NCT07207811·Phase 3·Recruiting·Listed Oct 2025
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
for Pulmonary Arterial Hypertension
Sites in Washington D.C. +14 more locations
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT07218029·Phase 3·Recruiting·Listed Oct 2025
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
for Non-small Cell Lung Cancer
Drug: Zongertinib
Sites in Washington D.C. +27 more locations
Sponsor: Boehringer Ingelheim
Sex: All·Age: 18+
Code: NCT07195695·Phase 3·Recruiting·Listed Sep 2025
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
for Endometrial Cancer
Sites in Washington D.C. +49 more locations
Sponsor: Genmab
Sex: Female·Age: 18+
Code: NCT07166094·Phase 3·Recruiting·Listed Sep 2025
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
for Secondary Progressive Multiple Sclerosis (SPMS)
Drug: Remibrutinib
Sites in Washington D.C. +34 more locations
Sponsor: Novartis Pharmaceuticals
Sex: All·Age: 18 - 65
Code: NCT07225504·Phase 3·Recruiting·Listed Nov 2025
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
for Metastatic Castration-resistant Prostate Neoplasms
Drug: Pasritamig
Sites in Washington D.C. +52 more locations
Sponsor: Janssen Research & Development, LLC
Sex: Male·Age: 18+
Code: NCT07164443·Phase 3·Recruiting·Listed Sep 2025
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
for Patients With Non-Small Cell Lung Cancer
Drug: OSE2101
Sites in Washington D.C. +33 more locations
Sponsor: OSE Immunotherapeutics
Sex: All·Age: 18+
Code: NCT06472245·Phase 3·Recruiting·Listed Jun 2024
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
for Parkinson's Disease
Drug: Prasinezumab
Sites in Washington D.C. +45 more locations
Sponsor: Hoffmann-La Roche
Sex: All·Age: 50 - 85
Code: NCT07174310·Phase 3·Recruiting·Listed Sep 2025
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
for Large B-cell Lymphoma
Sites in Washington D.C. +36 more locations
Sponsor: Lyell Immunopharma, Inc.
Sex: All·Age: 18+
Code: NCT07188558·Phase 3·Recruiting·Listed Sep 2025
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
for Chronic Obstructive Pulmonary Disease
Drug: Lunsekimig
Sites in Washington D.C. +51 more locations
Sponsor: Sanofi
Sex: All·Age: 40 - 80
Code: NCT07190222·Phase 3·Recruiting·Listed Sep 2025
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
for Triple Negative Breast Cancer
Sites in Washington D.C. +123 more locations
Sponsor: Gilead Sciences
Sex: All·Age: 18+
Code: NCT05633654·Phase 3·Recruiting·Listed Dec 2022
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
for Breast Cancer
Sites in Washington D.C. +168 more locations
Sponsor: Stemline Therapeutics, Inc.
Sex: All·Age: 18+
Code: NCT06492616·Phase 3·Recruiting·Listed Jul 2024
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
for Urothelial Carcinoma
Sites in Washington D.C. +142 more locations
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Sex: All·Age: 18+
Code: NCT04879329·Phase 2·Recruiting·Listed May 2021
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
for Pediatric Migraine
Sites in Washington D.C. +80 more locations
Sponsor: Pfizer
Sex: All·Age: 6 - 17
Code: NCT04649242·Phase 3·Recruiting·Listed Dec 2020
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
for Carcinoma, Non-Small-Cell Lung
Drug: Amivantamab
Sites in Washington D.C. +128 more locations
Sponsor: Janssen Research & Development, LLC
Sex: All·Age: 18+
Code: NCT06667076·Phase 2·Recruiting·Listed Oct 2024
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
for Breast Cancer
Sites in Washington D.C. +101 more locations
Sponsor: Pfizer
Sex: All·Age: 18+
Code: NCT07062965·Phase 3·Recruiting·Listed Jul 2025
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
for Proteinuric Kidney Disease
Sites in Washington D.C. +166 more locations
Sponsor: Vertex Pharmaceuticals Incorporated
Sex: All·Age: 10 - 65
Code: NCT05312879·Phase 2, Phase 3·Recruiting·Listed Apr 2022
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
for Migraine
Drug: Ubrogepant
Sites in Washington D.C. +89 more locations
Sponsor: AbbVie
Sex: All·Age: 6 - 17
Code: NCT05125302·Phase 3·Recruiting·Listed Nov 2021
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
for Carcinoma, Non-Small-Cell Lung
Drug: LY3537982
Sites in Washington D.C. +85 more locations
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT06890598·Phase 3·Recruiting·Listed Mar 2025
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
for Acute Treatment of Migraine
Drug: Rimegepant
Sites in Washington D.C. +61 more locations
Sponsor: Pfizer
Sex: All·Age: 6 - 17
Code: NCT04743141·Phase 3·Recruiting·Listed Feb 2021
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
for Early Breast Cancer
Drug: Ribociclib
Sites in Washington D.C. +84 more locations
Sponsor: Novartis Pharmaceuticals
Sex: All·Age: 18 - 100
Code: NCT05827081·Phase 3·Recruiting·Listed Apr 2023
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
for Diabetic Peripheral Neuropathic Pain
Sites in Washington D.C. +58 more locations
Sponsor: Vertex Pharmaceuticals Incorporated
Sex: All·Age: 18 - 80
Code: NCT06628908·Phase 3·Recruiting·Listed Oct 2024
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
for Carcinoma, Non-Small-Cell Lung
Drug: LY3537982
Sites in Washington D.C. +87 more locations
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT06119581·Phase 3·Recruiting·Listed Nov 2023
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
for Lymphoma, Large B-Cell, Diffuse
Drug: Polatuzumab Vedotin
Sites in Washington D.C. +70 more locations
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06890884·Phase 2·Recruiting·Listed Mar 2025
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
for Colorectal Neoplasms
Drug: Amivantamab
Sites in Washington D.C. +78 more locations
Sponsor: Janssen Research & Development, LLC
Sex: All·Age: 18+
Code: NCT06662786·Phase 3·Recruiting·Listed Oct 2024
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
for Advanced Non-Small Cell Lung Cancer
Drug: Adagrasib
Sites in Washington D.C. +191 more locations
Sponsor: Mirati Therapeutics Inc.
Sex: All·Age: 18+
Code: NCT04613596·Phase 2, Phase 3·Recruiting·Listed Nov 2020
Common conditions studied in District of Columbia
- Breast Cancer (16 active studies)
- Sickle Cell Disease (12 active studies)
- Stroke (12 active studies)
- High Grade Glioma (9 active studies)
- Prostate Cancer (9 active studies)
- Solid Tumor (9 active studies)
Leading research sponsors in District of Columbia
- Children's National Research Institute
- Georgetown University
- National Cancer Institute (NCI)
- Medstar Health Research Institute
- George Washington University
Frequently asked questions
How many paid clinical trials are currently recruiting in District of Columbia?
There are approximately 838 recruiting clinical trials in District of Columbia listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in District of Columbia pay participants?
Most recruiting trials in District of Columbia compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in District of Columbia?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in District of Columbia?
The most common conditions under active study in District of Columbia include Breast Cancer (16), Sickle Cell Disease (12), Stroke (12), High Grade Glioma (9), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in District of Columbia?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in District of Columbia on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in District of Columbia?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.